drugset / Trial / NCT01762839
A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study was to generate cardiac safety data using a supratherapeutic oritavancin dose of 1600 milligrams (mg).
Timeline
- Start
- 2012-12-27
- Primary completion
- 2013-01
- Completion
- 2013-02-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxifloxacin | Small molecule | 400 mg | — |
| Subject | Oritavancin | Other / unclassified | 1600 mg | Intravenous |
Indications
No indication recorded.